News & Information

Radialogica, a leading provider of radiation oncology quality management solutions, announced it has been selected by the Society of Interventional Oncology (SIO) to provide data collection, curation and analytics services for the TRIBUTE trial.

TRIBUTE is a prospective, multi-center observational study evaluating patients with symptomatic, high-risk bone metastases treated with percutaneous ablation and palliative radiation therapy (RT).  As part of its role, Radialogica will collect and analyze detailed information on the RT and ablation treatments delivered to patients, as well as follow-up imaging used to assess treatment response.

The TRIBUTE trial is supported through the collaboration of leading industry partners: Varian, a Siemens Healthineers Company; Stryker, Inc.; and Boston Scientific Corporation.

As the first prospective, multi-center study of its kind, TRIBUTE will generate real-world evidence on outcomes such as pain relief, patient-reported quality of life, skeletal-related events, and healthcare utilization in patients with metastatic bone disease. TRIBUTE represents the second major multi-industry supported clinical study launched by the SIO, following the ACCLAIM trial in 2021.

“The TRIBUTE trial represents an important milestone in advancing evidence for patients with metastatic bone disease,” said Jena Stack, SIO Executive Director. “Radialogica’s expertise in radiotherapy data curation and analytics ensures that we can reliably capture and analyze the treatment details needed to understand how ablation and radiation work together in real-world practice.”

“We are proud to support the SIO on the TRIBUTE trial and to contribute to a study that could help establish a new standard of care for metastatic bone cancer,” said Andrew Cowen, CEO of Radialogica. “Our work in RT quality assurance and data management will play a key role in evaluating how these therapies can improve outcomes and quality of life for patients with malignant bone metastases.”